Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model
Journal of Clinical Oncology · 01.09.2026 · 44 (25) · 2422-2434
DOI: 10.1200/jco-26-00347 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.09.2026. Verfasst von Curtis A Lachowiez und 50 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health and Science University, Portland, OR. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
PURPOSE As risk stratification for patients with AML treated with lower-intensity venetoclax-based therapy remains suboptimal, we developed and validated a prognostic model integrating clinical, cytogenetic, and molecular features. METHODS We assembled a multinational data set comprising 2,092 adults with newly diagnosed AML treated with hypomethylating agents plus venetoclax (HMA + VEN). One thousand nine hundred eighteen patients with complete data were randomly divided into training (70%) and internal validation (30%) cohorts. Two independent external validation cohorts were assembled (n = 500 and n = 222). Modeling overall survival (OS), Elastic Net regression was applied in 1,000 bootstrap samples from the training cohort to select variables for a Ridge regression, which generated a continuous Prognostic Risk Integration for Survival Modeling (PRISM) score and risk categories based on tertiles (PRISM-3: low, moderate, high). These PRISM indices were then computed for the validation cohorts and compared with the 4-gene classifier (based on mutations in FLT3 -ITD, N/KRAS , and TP53 ). RESULTS PRISM integrated 17 clinical and genomic variables and demonstrated a linear association with OS. PRISM-3 stratified survival consistently across all cohorts (median OS: 25.1-28.8 months for low risk, 12.5-14.7 months for moderate risk, and 5.8-6.7 months for high risk; P < .001). Compared with the 4-gene classifier, PRISM-3 reassigned approximately 40% of patients (and >50% of those with favorable risk) and demonstrated significantly better discrimination in validation cohorts (C-index 0.63-0.65 v 0.59-0.61; P < .05). CONCLUSION PRISM is a validated prognostic model for patients with AML receiving HMA + VEN that improves survival risk stratification beyond current standard tools and supports individualized, risk-adapted clinical decision making. The model, the PRISM-AML Risk Calculator, is publicly available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oregon Health and Science University, Portland, OR.
- University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
- Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.
- University of Sydney, Sydney, NSW, Australia.
- Haematology Department, Royal North Shore Hospital, St. Leonards, NSW, Australia.
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
ORCID-Profile: Curtis A Lachowiez, Joshua F Zeidner, Jad Othman, Andy Kaempf, Maël Heiblig, Michael Heuser, Rafael Madero Marroquin, Joseph M Cannova, Andrius Žučenka, Jennifer Marvin-Peek, Jayastu Senapati, Yasmin Abaza, Alok Swaroop, Irene Zacheo, Amine Belhabri, Emmanuelle Tavernier, Gaspar Aspas Requena, Elie Traer, Jennifer N Saultz, John Laurie, Shivani Handa, Eytan M Stein, Rebecca Olin, Gary Schiller, Emily Curran, Ashley Yocum, Naval Daver, Tapan M Kadia, Giovanni Marconi, Yazan Madanat, Richard Dillon, Courtney D DiNardo, Juan E Arango Ossa, Sanam Loghavi, Daniel A Pollyea, Elsa Bernard
Förderung
- NCATS NIH HHS
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Lachowiez, C. A., Zeidner, J. F., Othman, J., Kaempf, A., Yun, S., Heiblig, M., Heuser, M., Shahswar, R., Madero Marroquin, R., Cannova, J. M., Žučenka, A., Marvin-Peek, J., Senapati, J., Abaza, Y., Swaroop, A., Zacheo, I., Monaco, F., Belhabri, A., Tauveron-Jalenques, U., …, & PRISM-AML Investigators (2026). Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. Journal of Clinical Oncology, 44(25), 2422-2434. https://doi.org/10.1200/jco-26-00347
Vancouver
Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, et al. Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. Journal of Clinical Oncology. 2026;44(25):2422-2434. doi:10.1200/jco-26-00347
BibTeX
@article{Lachowiez2026,
author = {Lachowiez, Curtis A and Zeidner, Joshua F and Othman, Jad and Kaempf, Andy and Yun, Seongseok and Heiblig, Maël and Heuser, Michael and Shahswar, Rabia and Madero Marroquin, Rafael and Cannova, Joseph M and Žučenka, Andrius and Marvin-Peek, Jennifer and Senapati, Jayastu and Abaza, Yasmin and Swaroop, Alok and Zacheo, Irene and Monaco, Federica and Belhabri, Amine and Tauveron-Jalenques, Urbain and Tavernier, Emmanuelle and Carré, Martin and Aspas Requena, Gaspar and Cook, Rachel J and Traer, Elie and Saultz, Jennifer N and O'Nions, Jenny and Basheer, Faisal and Laurie, John and Handa, Shivani and Stein, Eytan M and Baer, Maria R and Olin, Rebecca and Blum, William and Schiller, Gary and Lin, Tara and Curran, Emily and Yocum, Ashley and Madarang, Ellen and Daver, Naval and Kadia, Tapan M and Marconi, Giovanni and Madanat, Yazan and Dillon, Richard and DiNardo, Courtney D and Swords, Ronan and Arango Ossa, Juan E and Watts, Justin and Loghavi, Sanam and Pollyea, Daniel A and Bernard, Elsa and PRISM-AML Investigators, PRISM-AML Investigators},
title = {Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {25},
pages = {2422--2434},
doi = {10.1200/jco-26-00347}
}
EUVIMED